Search for: "MERCK & CO., INC. " Results 301 - 320 of 663
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
12 Mar 2012, 5:41 pm by FDABlog HPM
Merck & Co., Inc., No. 33-av-00001 (D.N.J., Mar. 7, 2012) (Complaint) New England Carpenters Health and Welfare Fund v. [read post]
29 Jun 2018, 3:08 am by Brian Cordery
To recap, what are now known as Arrow declarations originate from the decision in Arrow Generics Ltd & Anor v Merck & Co, Inc [2007] EWHC 1900 (Pat), in which the High Court held that it had the discretion to grant a declaration that a medicinal product was obvious at the priority date. [read post]
28 Sep 2012, 11:15 am by Todd M. Nosher
Earlier this month, we reported that Merck & Co. had filed a petition for a Writ of Certiorari seeking to challenge the Third Circuit’s decision in In re K-Dur Antitrust Litig. holding that reverse payments are prima facie evidence of an antitrust violation. [read post]
20 Apr 2009, 2:24 pm
Docket: 08-905 Title: Merck & Co., Inc., et al., Petitioners v. [read post]
3 Dec 2009, 10:16 pm
Supporters can click the Make it Happen link and send an email to the CEOs of Abbott Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck & Co, Pfizer Inc. and Sequoia Pharmaceuticals Inc. [read post]
9 Nov 2015, 7:39 am
Some papers had reported that ligand PD-L2 binding generated a co-stimulatory signal whereas others reported PD-L1 was doing this. [read post]
30 Apr 2020, 3:30 am
Merck & Co., 46 USPQ2d 1478, 1479 (TTAB 1998) (citing Eurostar Inc. v. [read post]
25 Jan 2012, 9:00 pm by Stephanie Figueroa
Powers included Cisco Systems Inc., Merck & Co., MicrosoftCorp., Oracle Corp., Samsung Electronics Co., and Apple Inc. [read post]
25 Jan 2012, 9:00 pm by Stephanie Figueroa
Powers included Cisco Systems Inc., Merck & Co., MicrosoftCorp., Oracle Corp., Samsung Electronics Co., and Apple Inc. [read post]
11 Nov 2010, 12:54 pm by Bexis
Merck & Co., 2003 WL 22902622, at *3 n.3 (E.D. [read post]
12 Oct 2007, 6:02 am
In re Du Pont Merck Pharmaceutical Co., 34 USPQ2d 1778, 1781 (Comm'r Pat. 1995) ("In the present case, the issue regarding the proper signatory for an application and Statement of Use filed by a partnership Applicant is clearly one of procedure and practice under the rules, and is properly reviewable on petition"). [read post]